RxDoctor Payments Data

Abby McKinley, APRN

Family · Wichita, KSNPI 1518566512

Payments from drug & device makers

$2,820in general payments, 2019–2025

Across 195 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$554
  • Lilly USA, LLC$322
  • Bayer$257
  • Novo Nordisk$256
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$207
  • Merck$193
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,820100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,820 in reported general payments places this provider in the 90th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$31,087
Medicare patients
172
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$33,718
Epinephrine11$3,273
Pregabalin48$821
Albuterol Sulfate HfaAlbuterol Sulfate42$761
Levothyroxine Sodium84$518
Rosuvastatin Calcium67$449
Metformin Hcl37$448
Losartan Potassium63$431
Gabapentin43$401
Omeprazole22$354
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$351
Tamsulosin Hcl23$310
Duloxetine Hcl57$302
Tizanidine Hcl28$286
Fluoxetine Hcl34$280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$256$33,71832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,579 family providers in Kansas.

Other family in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →